Cybrexa Therapeutics Selects Lead Clinical Candidate CBX-11, Combining its alphalex™ Technology with an Approved PARP Inhibitor to Treat Various Solid Tumors in Combination with Chemotherapy CBX-11 selected based on robust efficacy and safety in combination with chemotherapy demonstrated in preclinical models Positive pre-IND Meeting with FDA supports on track plan to file IND in Q4 2019...

Cybrexa Therapeutics Presents Preclinical Data Demonstrating its alphalex™ Tumor Targeting Platform Delivers a High Dose of PARP Inhibitor in Combination with Chemotherapy Synergistic combination selectively kills tumors and prevents bone marrow toxicities Poster presentation today during 30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium Marks...

Cybrexa Therapeutics to Present Preclinical Data for its Tumor-Selective Technology Platform at the 30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium NEW HAVEN, Conn., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its tumor-selective technology platform, today...

Cybrexa Therapeutics Expands Scientific Advisory Board Ahead of IND Filing Dr. Geoffrey Shapiro and Dr. Timothy Yap bring extensive expertise in targeting cell-cycle and DNA repair mechanisms in oncology drug development NEW HAVEN, Conn., Oct. 22, 2018 (GLOBE NEWSWIRE) --...

Cybrexa Therapeutics Appoints Keely Zipp as Vice President of Marketing  NEW HAVEN, Conn., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an early-stage biotechnology company developing a new class of cancer therapeutics through its tumor-selective technology...